Kanamab (Ilaris) is a humanized monoclonal antibody that belongs to selective IL-1 β inhibitors. It is mainly used to treat various autoimmune inflammatory diseases by specifically blocking the inflammatory factor IL-1 β.

1. Basic information of the drug

(1) Common name: canakinumab

(2) Product Name: Ilaris

(3) R&D company: Novartis, Switzerland

(4) Approval time: First approved by FDA for CAPS treatment in 2009

2 Pharmacological mechanism of action

(1) Target effect: High affinity binding to free IL-1 β, blocking its interaction with IL-1 receptors

(2) Effect pathway: Inhibit downstream inflammatory signaling pathways, including NF - κ B and MAPK pathways

(3) Biological effect: Reduce C-reactive protein (CRP) and serum amyloid A (SAA) levels

3 main treatment areas

(1) Periodic fever syndrome: CAPS, FMF, TRAPS, etc

(2) Other indications: Systemic juvenile idiopathic arthritis (SJIA), gouty arthritis

(3) Extended study: Cardiovascular field (CANTOS trial) shows anti-inflammatory effects

4 Drug characteristics

(1) Molecular type: IgG1/κ monoclonal antibody

(2) Molecular weight: approximately 145kDa

(3) Half life: 26 days (supports dosing regimen every 8 weeks)

(4) Administration route: Subcutaneous injection